#USA #Richmond #BRAINBox #Richard Noel #TBI Tests

BRAINBox Solutions Announces Strategic Leadership Appointment

BRAINBox Solutions, a leading innovator in concussion management technology, has recently unveiled Richard H. Noel as its new Chief Product and Commercial Officer. This newly created role is expected to play a pivotal part in enhancing the company’s strategic direction and product offerings in the rapidly evolving field of diagnostics.

Richard Noel joins BRAINBox with an impressive background in molecular and point-of-care diagnostics, casting a broad net over over 10 years in the industry. He previously held significant positions at renowned organizations, including Roche Diagnostics, LumiraDx, and bioMérieux. His various roles have immersed him in market analytics and global product management, establishing him as a respected leader within the field.

According to BRAINBox Solutions’ CEO, Donna Edmonds, “Richard's profound expertise and strong track record at leading diagnostics firms make him exceptionally qualified to lead our efforts in commercial planning and the launch of our BRAINBox TBI concussion diagnostic and prognostic tests.” With Noel’s expertise, the company aims to redefine standard practices in concussion management.

Mr. Noel expressed enthusiasm about the opportunity at BRAINBox Solutions, stating, “BRAINBox has a unique chance to transform the standard of care for concussion management with its innovative TBI tests—the first objective assessments aimed at diagnosing and evaluating the potential for long-term complications.” He acknowledged the strong foundation established by the company, citing noteworthy product and clinical developments, as well as robust relationships with key figures in neurology and emergency medicine.

Bringing a wealth of experience from his previous ventures, Mr. Noel began his career in diagnostics as a market analyst at bioMérieux, where he quickly ascended to Global Product Manager. He expertly led various syndromic molecular diagnostic panels, analyzers, and software solutions. During his tenure at LumiraDx, he significantly influenced the marketing strategy and launch of their revolutionary SARS-CoV-2 Ag test amid the COVID-19 pandemic, propelling their North American point-of-care business from zero to an astounding $440 million in revenue within just two years. After LumiraDx was acquired by Roche Diagnostics in 2024, he facilitated the complete integration of its commercial operations.

Prior to immersing in the diagnostics sector, Richard Noel nurtured young minds by teaching honors physics, chemistry, and cognitive neuroscience. He boasts a Master's degree in Business and Biotechnology from the University of Utah, alongside a Bachelor's degree in Psychology from UC San Diego.

BRAINBox Solutions is on a mission to ascend as a leader in concussion management through its unique AI-enabled, multi-modality approach. Their flagship product, BRAINBox TBI, synergizes proprietary blood biomarker assessments with neurocognitive testing, furnishing an integrated score that appraises both the severity of injuries and the risk of post-concussion symptoms. The organization is presently wrapping up the pivotal HeadSMART II clinical trial, which encompasses more than 2,000 patients and is vital for FDA submission.

In addition to providing initial diagnoses, BRAINBox is committed to addressing the complete care continuum for head injuries—extending longitudinal monitoring and decision support for safe return-to-play, return-to-duty, and return-to-work. The company's R&D endeavors also encompass a patent-protected portfolio focused on neuro-related conditions, from mild traumatic brain injuries to neurodegenerative diseases. BRAINBox stands guided by a cadre of esteemed physician and scientific advisors in the realm of brain injury and neurology, reinforced by a clinically astute management team.

For more information about their innovative products and initiatives, visit www.brainboxinc.com.